Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Arezzo – page 74

1 011 clinical trials in Arezzo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Arezzo at a glance
1 011
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 011 trials in Arezzo

Open in trial search

Study on the Safety and Effectiveness of Sunvozertinib for Patients with Advanced Non-Small Cell Lung Cancer with EGFR or HER2 Mutations

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sunvozertinib
  • Sponsor:Dizal Pharmaceutical Co. Ltd.

Comparison of nilotinib versus imatinib treatment in newly diagnosed chronic myeloid leukemia patients to achieve treatment-free remission

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

General anaesthesia

Not recruiting

Study on the Effects of Low-Dose Sevoflurane, Dexmedetomidine, and Remifentanil Anesthesia on Neurodevelopment in Children Under 2 Undergoing Long Surgeries

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Sevoflurane
  • Sponsor:IRCCS Istituto Giannina Gaslini

Study on the Effectiveness and Safety of Avalglucosidase Alfa for Babies with Infantile-Onset Pompe Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Avalglucosidase Alfa
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study on Obinutuzumab, Chlorambucil, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Study on the Safety and Effectiveness of Crinecerfont for Adults with Classic Congenital Adrenal Hyperplasia

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.

Neoplasm

Not recruiting

Study on the Effectiveness of Inavolisib, Atezolizumab, and Entrectinib in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Fabry's disease

Not recruiting

Study on the Safety and Tolerability of ST-920 Gene Therapy for Patients with Fabry Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Sponsor:Sangamo Therapeutics Inc.

Actinic keratosis

Not recruiting

Study on the Safety of Tirbanibulin and Diclofenac Sodium for Adults with Actinic Keratosis on the Face or Scalp

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Diclofenac Sodium
  • Sponsor:Almirall S.A.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Arezzo

What the registry says about research in the country

01 Urological Oncology

Extensive research focusing on bladder cancer treatments, including innovative therapies combining immunotherapy with established treatments. Studies evaluate new approaches for both muscle-invasive and non-muscle invasive disease.

  • Bladder Cancer Immunotherapy
  • Urothelial Carcinoma Treatment
  • BCG Combination Therapies

Multiple trials exploring targeted treatments for patients with various stages of disease progression.

02 Prostate Cancer Research

Advanced studies examining new therapeutic approaches for metastatic prostate cancer, including novel drug combinations and targeted therapies for specific genetic mutations.

  • Castration-resistant Disease
  • Targeted Molecular Therapies
  • Hormone-based Treatments

Investigating innovative treatment sequences and combinations to improve patient outcomes.

03 Kidney Cancer Innovations

Cutting-edge research in renal cell carcinoma treatment, exploring immunotherapy combinations and targeted approaches for both early-stage and metastatic disease.

  • Immunotherapy Combinations
  • Targeted Molecular Agents
  • Advanced Disease Management

Focus on improving survival rates through novel therapeutic strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.